Shire opens $1.2bn, six-years-in-the-making facility

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/RobertoDavid)
(Image: Getty/RobertoDavid)

Related tags: Shire, Takeda

Shire’s immune globulin infusion-producing facility will increase the company plasma manufacturing capacity by one third.

The US facility encompasses an area more than one million-square-feet and cost $1.2bn (€1.05bn) to construct.

Based in Stanton Springs, Georgia, the space currently employs 900 staff members, but once the site is fully operational, this will increase to approximately 1,500 full-time staff.

Shire’s immunology portfolio proved key when it released its second-quarter financials, revealing that the segment delivered 13% growth and noting that this included “significant contributions from our subcutaneous immunoglobulin portfolio.”

The output at the facility will be gammagard liquid 10% solution, which is created from human plasma and used to deliver antibodies to patients with primary immunodeficiency.

The US Food and Drug Administration gave the site approval in June​ to produce the therapy. At the time, a spokesperson for Shire told us that the new site would improve the efficiency of the manufacturing process.

The spokesperson explained, “With fractionation, purification and filling at the same plant, Covington has the potential to increase efficiency and speed in the manufacturing process to bring our plasma-derived therapies to patients faster.”

Plans for the site were originally begun through the company Baxalta, which was acquired by Shire in 2016. Now, Shire stands ready to be acquired by Takeda​, meaning that the facility will have changed hands three times in as many years.

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...


Inline concentration improves process economics

Pall Biotech | 15-Jun-2018 | Case Study

Would you like to enhance your downstream process, increase production capacity and reduce costs? This case study application note demonstrates how implementing...

Related suppliers

Follow us


View more